Artivion (NYSE:AORT – Get Rating) and PolyPid (NASDAQ:PYPD – Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership. Valuation and Earnings This table compares Artivion and PolyPid’s top-line revenue, […]
Cerus (NASDAQ:CERS – Get Rating) and Artivion (NYSE:AORT – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations and institutional ownership. Profitability This table compares Cerus and Artivion’s net margins, return on […]
Artivion (NYSE:AORT – Get Rating) released its quarterly earnings results on Thursday. The company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.15, Fidelity Earnings reports. Artivion had a negative net margin of 4.95% and a positive return on equity of 3.06%. AORT traded down $0.82 during […]